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Toll-like receptor (TLR) signaling is subjected to crosstalk from other signals, with a resulting positive or neg-
ative effect. There is complex crosstalk between the NLR family of immune-regulatory molecules and TLRs,
and C-type lectin receptors such as Dectin-1 synergize with TLR2 via the tyrosine kinase Syk. Bruton’s tyro-
sine kinase plays an important positive role in TLR signaling, whereas the TAM family of receptor tyrosine
kinases is inhibitory. The tyrosine phosphatase SHP1 has been shown to positively regulate induction of
interferon-b, whereas SHP2 inhibits the kinase TBK1, limiting this response. K63-linked polyubiquination
has also been shown to be critical for the initiation of TLR signaling. Finally, glucocorticoids affect TLR sig-
naling by inducing the phosphatase MKP1 and inhibiting TBK1 activation. These recent findings emphasize
the importance of considering TLR signaling in the context of other signaling pathways, as is likely to occur in
vivo during infection and inflammation.In order to have a molecular understanding of the immune re-
sponse,we needadetailed description of signaling pathways ac-
tivated by the multitude of sensors of the products of microbes.
These products can be peptides presented via the major histo-
compatibility complex (MHC) in antigen-presenting cells toT lym-
phocytes. Arguably more is known about the biochemical events
that occur in T cells when the T cell receptor is activated (and as-
sociated costimulatory receptors) than any other cell in the body.
Signaling in T cells has been a major focus for molecular immu-
nologists, and for good reason, given the central importance of
T cells for host defense and the ongoing complexities of T cell
subsets being revealed in different contexts.
There has also been an explosion of information on receptors
on front-line host defense cells such as macrophages and den-
dritic cells (DCs), which when activated lead to a change in gene
expression. The genes that are expressed code for proteins im-
portant for inflammation, for innate immunity, and also for the
instruction of T and B cells in the adaptive arm of immunity.
These receptors are grouped together under the heading of
innate immunity because there is no rearrangement of gene
segments in their generation and no apparent memory response
involving the cells that express them. Much progress has been
made on how these innate sensors signal. However it has also
become apparent that there is complex positive and negative
regulation of the signaling pathways activated as a result of
crosstalk with other signals. This review will discuss the recent
progress in our understanding of this aspect of innate signaling.
These advances will be important for our overall understanding
of the molecular regulation of innate immunity during infection
and inflammation.
Types of Innate Sensors
The best-known class are the Toll-like receptors (TLRs), and
other classes include the NOD-like receptors (or recently defined12 Immunity 29, July 18, 2008 ª2008 Elsevier Inc.as nucleotide-binding domain and leucine-rich repeat contain-
ing molecules [NLRs]), RIG-I-like receptors (RLRs), and C-type
lectin receptors (CLRs) (Creagh and O’Neill, 2006; Willment
and Brown, 2008). All of these respond to various microbial
products, with the TLRs providing a repertoire to respond to all
pathogens, be they bacterial, viral, fungal, or parasitic (Bowie
and O’Neill, 2007). The best characterized are TLR2, which in
combination with TLR1 or TLR6 can recognize acylated lipopep-
tides; TLR3, which senses double-stranded RNA; TLR4, which
senses LPS; and TLR9, which senses hypomethylated CpG
motifs.
NLRs that have been assigned functions include NOD1 and
NOD2, which sense iE-DAP and MDP, respectively (Kanneganti
et al., 2007b). Both of these are breakdown products of peptido-
glycan. In addition, Nalp3 (also called Cryopyrin of Nlrp3) senses
multiple pathogens, pathogen products such asMDP, and prod-
ucts of damaged cells such as uric acid crystals and exogenous
crystals such as asbestos (Martinon et al., 2004, 2006; Dostert
et al., 2008). The best-known RLR is RIG-I, which senses sin-
gle-stranded RNA found in viruses (Yoneyama et al., 2004),
and the best known CLR is Dectin-1, which senses beta-glucan,
found in fungal cell walls (Brown et al., 2002).
Signaling Components of the Innate Sensors
An important signal activated by TLRs, NOD1, NOD2, and Dec-
tin-1 is the transcription factor NF-kB, which regulates the ex-
pression of many immune and inflammatory genes (Bowie and
O’Neill, 2007). They also activate the MAP kinases p38 and
ERK1 and/or ERK2, which also play a role in enhanced gene
transcription and, in the case of p38, the stability of induced
mRNA species containing AU repeats in their 30 ends. Nalp3,
in contrast, is found in an inflammasome with caspase-1 and
is important for caspase-1 activation (Martinon, 2008). This is
the enzyme that processes the proform of IL-1b into its mature
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which is also activated by TLRs involved in viral recognition.
IRF3 regulates the production of type I interferons (Yoneyama
et al., 2004). IRF7 has also been shown to play an important
role in the induction of type I interferons by TLRs (Honda et al.,
2005).
There has been remarkable progress in understanding how
these innate sensors signal. ‘‘New’’ signaling proteins, protein
kinases, and transcription factors have been found, representing
a major advance in knowledge in immune cell signaling. In the
case of TLRs, a family of five signaling adapters was found
(Bowie and O’Neill, 2007). The defining domain is the Toll-lL-1
receptor (TIR) domain, which occurs on the cytosolic face of
the receptors, and also in the adapters. Recruitment of the
adapters to the TLR cytosolic face allows signaling to proceed.
However, no signaling pathway occurs in isolation in cells, es-
pecially in vivo. Recently, insights into other signaling pathways
that affect TLR signaling have been described. Some of these
will have a positive effect and synergize (e.g., the reported syn-
ergies between NOD1 or NOD2 or Dectin-1 with certain TLRs
for activation of signals such as NF-kB [Tada et al., 2005; van
Heel et al., 2005; Dennehy et al., 2008]), whereas others will
have a negative effect (e.g., activation of the Tyro Axl Mer
(TAM) family of tyrosine kinases, which inhibits TLR signaling
[Rothlin et al., 2007]). Some processes can be both positive
and negative, as can be seen with ubiquination of proteins on
the pathway, which can either activate (e.g., K63-linked ubiqui-
nation of TRAF6 on the NF-kB pathway (Deng et al., 2000;
Wang et al., 2001) or lead to degradation (e.g., K48-linked ubiq-
uitination of IkB). Although trying to understand a signaling
pathway in isolation has its challenges, integrating multiple path-
ways, as would occur in vivo, provides us with a very demanding
goal, whichmust be achieved if we are to understand signaling in
health and disease.
TLR Signaling Adapters—an Update
The area of signaling by the TLR adapters has been reviewed ex-
tensively elsewhere (Bowie and O’Neill, 2007). In brief, the model
currently used to describe initiation of signaling involves ligand-
induceddimerization of TLRs, creating a TIR-TIR interface, which
acts to recruit adapters via their TIR domains (Weber et al., 2005).
In the case of TLR9, it has been shown that a pre-exising dimer
occurs, which presumably ‘‘tightens’’ upon ligand binding to
create a new conformation (Latz et al. (2007)). Specificity is
evident in adaptor usage by different TLRs (Bowie and O’Neill,
2007). MyD88 is the universal adaptor, used by all TLRs except
TLR3, and acts to recruit the IRAK family of kinases. These
ultimately trigger NF-kB, p38, and ERK activation. MyD88 adap-
tor-like (Mal, also called TIRAP) is recruited by TLR2 and TLR4,
and so far its main function appears to be to subsequently stabi-
lizeMyD88 in the complex, actingasabridge. Trif is usedbyTLR3
andalsoTLR4,but in thecaseofTLR4anotherbridgingadaptor is
needed, Tram. Trif leads to IRF3 activation via recruitment of the
kinase TBK-1, and this signal, in the case of both TLR3 and TLR4,
comes from the endosome, with TLR4 trafficking there after LPS
recognition (Tanimura et al., 2008; Kagan et al., 2008). Finally, the
adaptor SARM has been shown to inhibit Trif and therefore may
be a negative regulator (Carty et al., 2006). We therefore have
an increasingly clear picture of the initiation of TLR signaling.We also have a good picture of the covalent regulation of com-
ponents in TLR signaling. The role of phosphorylation by tyrosine
kinases in the regulation of TLR signaling will be discussed in de-
tail below, given recent advances. Similarly, there have been
advances in the regulation of signaling by ubiquitination that
will be discussed below. In addition, the cell biology of the
adapters in TLR signaling is becoming clearer. For example,
Mal has a phosphatidylinositol-4,5-bisphosphase (PIP2) binding
domain that localizes it to the plasma membrane (Kagan and
Medzhitov, 2006), whereas TRAM is myristoylated for the same
reason (Rowe et al., 2006). A recent important insight into
TLR4 signaling has come from the observation that it is the
localization of TLR4 that determines whether the Mal-MyD88
pathway or the TRAM-TRIF pathway is activated (Tanimura
et al., 2008; Kagan et al., 2008). TLR4 in the plasma membrane
engages with Mal and subsequently MyD88, for NF-kB activa-
tion via TRAF6. TLR4 will then traffic to endosomes, where
TRAM is now engaged, recruiting TRIF, which in turn recruits
TRAF3 to activate TBK-1. Binding of Mal and TRAM appear to
be mutually exclusive (Nu´n˜ez Miguel et al., 2007). This gives us
an explanation for how TLR4 can engage with TBK-1 because
the other receptors that activate this kinase are cytosolic or en-
dosomal (e.g., TLR3). Phosphorylation of TRAM on serine 16 by
protein kinase C-epsilon is required for this process (McGettrick
et al., 2006) and may be required for endosomal trafficking or
displacement of Mal-MyD88 from the complex.
The broad family of TIR adapters also continues to grow. The
latest mammalian member, SARM, has been shown to inhibit
signaling by TRIF and is therefore a negative regulator of the
IRF3 pathway (Carty et al., 2006). It has also been shown to be
expressed in neurons, where it interacts with the MAP kinase
JNK3 (Kim et al., 2007). It appears to have a damaging role in
brain because it has been demonstrated to be involved in the
death of hippocampal neurons as a result of deprivation of oxy-
gen and glucose. How this fits with its role as a regulator of TRIF
is not clear, and there may be an important species difference
between mouse and human in this regard; its role in TRIF regu-
lation may be more relevant to humans. TIR adapters also
continue to be uncovered in other species, a recent and striking
example being in various bacteria. The first report of this was in
Salmonella enteritica serovar, which was shown to have a TIR-
like protein that impairs TLR signaling, promoting intracellular
bacterial accumulation (Newman et al., 2006). A uropathogenic
strain of E. coli, termed CFT073, was then shown to have
a TIR-domain-containing protein termed TIR-containing protein
C (TcpC) (Cirl et al., 2008). The bacteria release this protein,
which is somehow taken up by macrophages, where it interacts
with MyD88 to prevent signaling. This is important to promote
bacterial survival but also kidney pathology. Decoy adapters
had been reported previously in Vaccinia virus (Bowie et al.,
2000; Harte et al., 2003; Stack et al., 2005) and would therefore
appear to be a common strategy for pathogens to evade innate
immune responses. Several other bacterial species have TIR do-
main-containing proteins (Cirl et al., 2008), and this is likely to be
a very fruitful area of research for those interested in virulence.
There have also been reports on single-nucleotide polymor-
phisms in the adapters that regulate their function, the best
example so far being the S180L variant in Mal (Hawn et al.,
2006; Khor et al., 2007; Castiblanco et al., 2008). The leucineImmunity 29, July 18, 2008 ª2008 Elsevier Inc. 13
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ReviewFigure 1. Crosstalk between TLRs and
Nalp3
The induction of mature IL-1b is a complex inter-
play between TLRs and Nalp3. TLRs such as
TLR4 and TLR7 activate the standard signaling
pathway via MyD88 and NF-kB to induce pro-
IL-1b mRNA. Various stimuli act via Nalp3 to acti-
vate caspase-1, which processes the pro-IL-1b
protein into mature IL-1b. These stimuli include
ATP, MDP, uric acid, and asbestos. A potassium
efflux appears to be required, although how this
occurs is still not fully worked out, nor is its role
in Nalp3 activation. Uric acid and asbestos have
been shown to activate NADPH-oxidase-generat-
ing reactive oxygen species (ROS), which are also
required for Nalp3 activation, although again
a mechanism is missing. Finally, LPS and R837
prime the Nalp3 inflammasome for activation
and, intriguingly, this appears to be TLR indepen-
dent.form ofMal is fundamentally impaired andmay act to temper sig-
naling by the serine form. Heterozygotes are protected against
multiple infectious disease, including malaria and TB (Khor
et al., 2007; Castiblanco et al., 2008), and also in systemic auto-
immune disease such as systemic lupus erythematosus (SLE)
(Castiblanco et al., 2008). These studies confirm the importance
of TLR signaling in human disease.
Crosstalk with Other Innate Receptors
The first example of where there has been progress regarding
crosstalk is with other receptors involved in innate immunity.
Because it is highly unlikely that the host will be exposed to single
ligands for innate receptors during infection, a more physiologi-
cal although challenging approach is to examine activation of
signaling by multiple ligands simultaneously. The most studied
combination so far is to examine TLR and NLR ligands. A
clear-cut example of this ‘‘two-signal’’ approach is the ability
of TLRs to induce pro-IL-1b production, but without causing
processing to the mature cytokine, as shown in Figure 1. If cas-
pase-1 is active, however, this processing will occur (Martinon,
2008). Nalp3 is a key component of an important caspase-1-
containing inflammasome and is activated by various patho-
gens; such substances as ATP, MDP (Martinon et al., 2004);
uric acid crystals (Martinon et al., 2006); and, most recently,
other types of crystals such as asbestos and silica (Dostert
et al., 2008). Themechanism of Nalp3 activation has been shown
to involve a potassium efflux, mediated by the P2X7 receptor in
combination with the ion channel pannexin-1 (Kanneganti et al.,
2007a). It also appears to involve reactive oxygen species (ROS)
generated by the NADPH oxidase, although how the potassium
efflux or ROS generation leads to Nalp3 activation is not known.
TLR ligands such as LPS or the TLR7 ligand R837 also modulate
the inflammasome, enabling ATP to activate caspase-1 via
Nalp3. Intriguingly this phenomenon appears to be independent
of TLRs because it occurs in MyD88-, Mal-, and Trif-deficient
macrophages and, in the case of R837, in TLR7-deficient macro-
phages (Yamamoto et al., 2004; Kanneganti et al., 2006; Maria-
thasan et al., 2006; Miggin et al., 2007) (Figure 1).14 Immunity 29, July 18, 2008 ª2008 Elsevier Inc.How ligands such as ATP, MDP, and uric acid crystals in this
context are sensed is therefore unclear. It could be via induction
of inflammasome components, although given the lack of a role
for TLRs, this seems unlikely. It is also possible that the effect
here is via modulation of ROS in some way, possibly via effects
on the NADPH oxidase. Caspase-1 has also been shown to be
constitutively active in monocytes, unlike macrophages, where
it requires activation (Netea et al., 2008). This is likely to be due
to monocytes being a ‘‘front-line’’ blood cell and will release
mature IL-1b after induction of the proform.
Similarly synergies occur between TLRs and NOD1 or NOD2
(Tada et al., 2005; van Heel et al., 2005; Kanneganti et al.,
2007b). TLRs and NOD1 or NOD2 have been shown to signal
to NF-kB via the protein kinase RICK, which could be a point
of synergy (Kobayashi et al., 2002). This is somewhat controver-
sial, however, because there have also been reports that NOD2
ligands such as MDP inhibit signaling by multiple TLRs. This
inhibitory effect was shown to involve IRF4 (Watanabe et al.,
2008). In addition, Nod1- and Nod2-mediated signaling has
been shown to be enhanced in macrophages made tolerant to
TLR activation (Kim et al., 2008). This could be a fail-safe
mechanism to allow host defense responses to intracellular
pathogens. More mechanistic work is needed on these combi-
natorial experiments to provide clearer insights.
A more straightforward synergy has been reported between
theCLRDectin-1 and TLRs (Dennehy et al., 2008). Dectin-1 is es-
sential for the innate response to fungal pathogens (Brown et al.,
2002; Taylor et al., 2007). Its ligand is beta-1,3-glucan, and it sig-
nals via the tyrosine kinase Syk and the protein CARD9 (Hara
et al., 2007) Clear synergies between Dectin-1 and TLR2 have
been reported, although the fungal ligand for TLR2 awaits defini-
tion. Syk is absolutely required for this synergy, as is MyD88
(Dennehy et al., 2008). The role for Syk here contrasts with the in-
hibitory effect of DAP12 described below, because DAP12 has
also been shown to require Syk to signal. The basis for this differ-
ence is not known, although the downstream signals activated
by Syk in both cases might differ. As with the other synergies
discussed here, we await a detailed mechanistic explanation.
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Kinases, Tyrosine Phosphatases, and
Glucocorticoids
Multiple signaling pathways interact with TLR4
signals. Bruton’s tyrosine kinase and in certain
cell types Bmx are required for TLR4 signaling.
Btk is on a pathway that leads to the phosohory-
lation of p65 on serine 536. It is also required for
induction of IL10, IL6, and TNF. TREM1 and
DAP12, probably acting via phospholipase
C-gamma, limits TLR4 signaling. TAM receptors
in a complex with IFNAR1 induce SOCS1, which
inhibits TLR4 by targeting Mal, and SOCS3, which
inhibits TRAF3 and TRAF6. TLR4 in endosomes
recruits TRAM and TRIF, leading to TRAF3 activa-
tion. This pathway leads to TBK1 activation, which
is required for IRF3 phosphorylation. The tyrosine
phosphatase SHP1 inhibits IRAK1, limiting NF-kB,
but in addition, this somehow boosts interferon-
b production (not shown). SHP2, in contrast,
inhibits TBK1 activation, blocking this response.
Finally, glucocorticoids target the IRF3 pathway
at multiple points—inhibition of a p65-IRF3 com-
plex, disruption of the transactivator GRIP1, and
inhibition of TBK1.Crosstalk Via Tyrosine Kinases and Phosphatases
The second example of crosstalk recently characterized con-
cerns the regulation of TLR signaling by tyrosine kinases and
phosphatases (Figure 2). The role of tyrosine kinases in TLR sig-
naling has been explored for a number of years, particularly in
TLR4 signaling. LPS had been shown to increase tyrosine phos-
phorylation in cells, and various candidate tyrosine kinases have
been suggested to participate in this process. Notably, the tyro-
sine kinases Src, Hck, and Lyn have been shown to be activated
by TLR4, although their exact role is uncertain because a hck,
fyn, lyn triple-deficient mouse was normal for TLR4 signaling
(Meng and Lowell, 1997). More recently, Tec-family tyrosine
kinases have been analyzed, and a role for Bruton’s tyrosine
kinase (Btk) in TLR4 signaling (and other TLRs such as TLR2,
TLR4, TLR7-TLR8, and TLR9 [Jefferies et al., 2003; Horwood
et al., 2003; Liljeroos et al., 2007; Doyle et al., 2007; Lee et al.,
2008]) has been indicated. Btk is recruited to both TLR4 and
TLR9 and has been shown to be involved in the pathway leading
to enhanced phosphorylation of the p65 subunit of NF-kB on ser-
ine 536, which is required for p65 to promote gene expression
(Doyle et al., 2005, 2007; Lee et al., 2008). In B cells, Btk is
required for TLR9-induced proliferation and IL-10 production
(Lee et al., 2008). Btk is also required for IL-10 induction by
TLR4 in macrophages (Schmidt et al., 2006). These effects on
IL-10 can confound cytokine readouts because in Btk-deficient
cells there have been reports of enhanced IL-12 and IL-6
production, which is due to the decrease in IL-10, leading
to a loss of autocrine inhibition of these cytokines. There are
inconsistencies in the literature, however, because in human
peripheral blood mononuclear cells there appears to be no role
for Btk in IL-6 induction in response to TLR2 or TLR4 (Horwood
et al., 2006). There is a role in TNF production, however, which
was shown to be due to Btk’s being required for p38 activation,which then stabilizes TNF but not IL-6 mRNA. Another Tec family
member, Bmx, has been shown to be required for TLR4-induced
IL6 production in macrophages and rheumatoid arthritis synovial
cells (Palmer et al., 2008a, 2008b), via mRNA stabilization,
although the mechanism is not known.
Most notably, cells from patients with X-linked agammaglob-
ulinemia, which harbor a mutation in Btk, are defective in their
capacity to synthesize cytokines in response to TLR2, TLR4,
TLR7-TLR8, and TLR9 (Doyle et al., 2007; Taneichi et al.,
2008). The precise downstream targets for Btk are, however, still
unclear. One substrate isMal (Gray et al., 2006; Piao et al., 2008),
which undergoes phosphorylation by Btk on Tyr-86 and Tyr-106.
This event is required for Mal to signal NF-kB activation but, in
addition, is involved in the ultimate degradation of Mal via the
recruitment of suppressor of cytokine signaling 1 (SOCS1) (Man-
sell et al., 2006). This appears to be an important aspect of
SOCS1—mediated inhibition of TLR4 signaling. This phosphory-
lation of Mal has also been shown to be impaired in cells
rendered tolerant to LPS (Piao et al., 2008).
An inhibitory role for proteins with an immunoreceptor tyro-
sine-based activation motif (ITAM) toward TLR signaling has
also been suggested (Hamerman et al., 2005). At first, this
seemed counterintuitive, because ITAM-containing proteins
that couple to receptors had been shown to activate signaling
pathways leading to inflammatory cytokine production, such
as DAP12, which couples to the coreceptor TREM-1. The tyro-
sine kinase Syk plays a key role in DAP12 activation, phosphor-
ylating tyrosine residues, and allowing for the recruitment of
SH2-domain-containing proteins such as the p85-p110 dimer
of PI3 kinase and phospholipase Cg. TREM-1 had been shown
to synergize with TLR4 in the induction of proinflammatory cyto-
kines (Bouchon et al., 2001). However, DAP12-deficient mice
were shown to be more responsive to TLR stimulation,Immunity 29, July 18, 2008 ª2008 Elsevier Inc. 15
Immunity
Reviewproducing higher quantities of cytokines in response to various
TLR ligands (Hamerman et al., 2005). It therefore appears that
DAP12-associated receptors inhibit TLR signaling by an un-
knownmechanism. One interesting aspect of this area is a recent
paper demonstrating that CD32A (a so-called ‘‘activating’’ Fcg
receptor), which has an ITAM, inhibits TLR signaling (Dunn-Sieg-
rist et al., 2007). This was shown through the use of an antibody
to TLR4, whose inhibitory effect was shown to be dependent on
Fcg receptor signaling. The effect here appears to be proximity
dependent—the antibody binds to TLR4 and the Fc portion
binds to CD32A, bringing it into close proximity to TLR4. How
it inhibits TLR4 is not clear, however. It might involve activation
of PI3 kinase, which via Akt has been shown to block NF-kB
activation by TLR4. Alternatively, because CD32A can activate
phospholipase C-g, a depletion in PIP2 by this enzyme might
lead to Mal’s dissociation from the plasmamembrane. Depletion
in PIP2 would therefore be expected to limit TLR4 signaling. This
capacity of Fc receptors to inhibit TLR4 might be physiologically
relevant because it is possible that once adaptive immunity is es-
tablished, limiting innate immunity via Fc receptors might protect
the host from deleterious effects of inflammation and sepsis.
Further evidence of tyrosine kinases inhibiting TLR signaling
has come from studies into the TAM family of receptor tyrosine
kinases (Rothlin et al., 2007). When originally characterized, the
TAM receptors were orphans. Two agonists were then found—
growth-arrest-specific 6 (Gas6) and protein S (Stitt et al.,
1995). Gas6 binds all three, although with different affinities. Pro-
tein Smay be specific for Tyro. A triple-deficient mousewas gen-
erated in order to determine the function of these receptors.
These mice had a clear immune phenotype—they developed
a systemic autoimmune disease. The basis for this appeared
to be a lack of inhibition of signaling by TLRs in the mice. The
mechanism was a failure to induce SOCS1 and SOCS3, proteins
that inhibit JAK-STAT signaling pathways, as well as TLR signal-
ing (Rothlin et al., 2007). The ligands for the TAM receptors Gas6
and Protein S activate a signaling pathway via the R1 subunit of
the type I interferon receptor, which has been shown to occur in
a complex with Axl. This leads to activation of STAT1 and, in turn,
induction of SOCS1 and SOCS3, which act to block TLR signal-
ing. If mice are deficient in TAM receptors, this pathway doesn’t
occur and TLR signaling is potentiated. That autoimmunity re-
sults tells us that altered innate immunity is sufficient to promote
dysfunctional B and T lymphocyte activation.
Tyrosine phosphatases can negatively regulate certain TLR
responses. SH2-containing protein tyrosine phosphatase 1
(SHP1) is an intracellular tyrosine phosphatase that contains
two tandemly linked SH2 domains at its amino terminus, fol-
lowed by a catalytic domain. It has been shown that SHP1 neg-
atively regulates TLR-mediated production of proinflammatory
cytokines by inhibiting activation of NF-kB and MAP kinases
(An et al., 2008). Intriguingly, SHP1 promotes production of
type I interferons by TLRs and also RIG-I. The mechanism in
both cases appears to be SHP1 binding to the kinase domain
of IRAK-1 (which contains several phosphoaccepting tyrosines),
where it inhibits its activity. This kinase activity is required for
induction of proinflammatory cytokines, but is somehow inhibi-
tory for induction of type I interferons, because autophosphoyla-
tion of IRAK1 leads to its degradation, allowing for increased pro-
duction of type I interferons (An et al., 2008). IRAK1 may be16 Immunity 29, July 18, 2008 ª2008 Elsevier Inc.acting as a bridging adaptor for the pathway to type I interferon
production, although there is conflicting evidence regarding its
action as a kinase to phosphorylate IRF7, which is required for
type I interferon gene transcription (Uematsu et al., 2005).
The related SHP, SHP2, also negatively regulates TLR signal-
ing, but its effect is more specific (An et al., 2006). SHP2 limits
TLR3-induced production of proinflammatory cytokines and
interferon-b, without affecting TLR2 or TLR9 signaling. In this
case, SHP2 was shown to target TBK-1, the kinase that phos-
phorylates IRF3. Although related, therefore, SHP1 and SHP2
have opposite effects. SHP1 promotes interferon-b production
in response to TLRs, whereas SHP2 is inhibitory. Clearly, the
overall mechanism here is for each SHP to bind to phosphotyro-
sine residues on specific substrates, limiting the function of the
target. In the case of SHP1 this is IRAK1, whereas for SHP2 it
is TBK-1. How this binding translates into an inhibitory effect is
still unclear.
Regulation via Ubiquination
The third example of crosstalk concerns regulation of TLR sig-
naling by ubiquitination. An extensive literature on this subject
has been building up recently. Various ubiquitin ligases have
been implicated, and in fact some of the components found in
TLR signaling turn out to be ubiquitin ligases themselves. The
recent literature is allowing us to establish the earliest catalytic
events in TLR signaling, which involve both phosphorylation
and ubiquitination of components, leading to their activation
and/or degradation (Figure 3). As described above, TLR signal-
ing (with the exception of TLR3) is initiated by the recruitment
of MyD88 to the TLR complex. This in turn leads to the recruit-
ment of IRAK1 and IRAK4. IRAK4 then activates IRAK1, allowing
IRAK1 to autophosphorylate. Both IRAK1 and IRAK4 then disso-
ciate fromMyD88, which remains in a complex with the activated
receptor—this has been shown for IL-1RI and will most probably
apply to the TLRs (Brikos et al., 2007). They in turn interact with
TRAF6, which is an E3 ubiquitin ligase. TRAF6 is then thought to
autoubiquinate, attaching K63-polyubiquitin to itself. The E2-
conjugating complexes Ubc13 and Uev1a are also involved in
this process (Deng et al., 2000). K63-polyubiquitin-TRAF6 can
then recruit TAK1 in a complex with TAB2 and TAB3, which
both contain nuclear zinc-finger motifs that interact with K63-
polyubiquitin chains. This somehow activates TAK1, which
then couples to the IKK complex, which contains the scaffold
protein NEMO and the kinase responsible for phosphorylation
of I-kappaB, IKK2. TAK1 also couples to MKK3-MKK6 and
MKK7, the respective upstream kinases for p38 and JNK.
The situation regarding the initiation of TLR signaling is likely
to be more complex, however. It has been shown that another
member of the IRAK family, IRAK2, appears to be more impor-
tant than IRAK1 in the pathway to Traf6 ubiquitination. This is
particularly the case for TLR3, which doesn’t signal via IRAK1
or IRAK4 (Keating et al., 2007). The IRAK2-deficient mouse
has also recently been described (Kawagoe et al., 2008). It
was shown that similar to IRAK1, IRAK2 was activated down-
stream of IRAK4. Also similar to IRAK1, IRAK2 is essential for
signaling because TLR-induced cytokine production was abro-
gated in the absence IRAK2. Importantly, the role of IRAK2 was
in the sustained activation of NF-kB. Finally, IRAK2 was shown
to possess kinase activity. This was thought to be unlikely
Immunity
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TLRs
A clearer picture of how TLRs lead to activation of
NF-kB activation has emerged. Phosphorylation
and ubiquitination are key covalent modifications
in this process. Signaling is initiated by ligand
binding, shown here for IL-1, LPS, and pIC. In IL-1
signaling, MyD88 is recruited to the receptor
complex within seconds, where it stably associ-
ates. For TLR4, Mal is required to recruit MyD88.
IRAK4 and IRAK1 (and probably IRAK2) are then
recruited toMyD88. For TLR3, IRAK2 is directly re-
cruited. IRAK4 then phosphorylates IRAK1, and
the kinases dissociate from MyD88. IRAK1 phos-
phorylates Pellino-1. IRAK2 probably dissociates
from TLR3, although the mechanism is not known.
Pellino-1 is an E3-ligase that causes K63-polyubi-
quination of IRAK1. This serves as a platform to re-
cruit the NEMO-IKK1-IKK2 complex. IRAK2 leads
to K63-linked polyubiquitination of TRAF6, which
serves as a platform to recruit TAK1. TAK1 then
activates IKK2 in the NEMO-IKK1-IKK2 complex.
IRAK1 has a similar role to IRAK2—it leads to
K63-linked polyubiquitination of TRAF6 and
TAK1 recruitment. This brings TAK1 into close
proximity with IKK2 in the NEMO-IKK1-IKK2 com-
plex, activating IKK2. How NEMO-IKK1-IKK2 is
brought into proximity with TAK1 in the IRAK2
pathway is not known. IRAK2 has also recently
been shown to be important for the sustained
activation of NF-kB downstream of IRAK4 and
IRAK1, with the possible exception of TLR3.because it was predicted to be a pseudokinase. Consistent
with its role in a sustained response, IRAK2 kinase activity
was sustained and peaked at 8 hr after stimulation, unlike
IRAK1, which peaked at 1 hr stimulation. It therefore appears
that IRAK1 and IRAK2 act in sequence, with both being essen-
tial for cytokine induction by TLR2. No role for IRAK2 was found
in TLR3 signaling, however, because this was normal in the
IRAK2-deficient mice.
There is also new complexity in our understanding of IRAK1
function. In response to IL-1 (and, by analogy, presumably the
TLRs, given that the IL-1 type I receptor signals via MyD88),
IRAK1 undergoes K63-linked polyubiquination. Two proteins,
termed Pellino-1 and Pellino-3b, appear to be important in this
process (Butler et al., 2007;Ordureau et al., 2008). Theseproteins
were known to interact with IRAK-1, and recent studies indicate
that similar to Traf6, they are E3 ligases. Importantly, their activity
is greatly enhanced, at least in vitro, in response to phosphoryla-
tion by IRAK1 and IRAK4. The role of the kinase activity of IRAK1
and/or IRAK4 might therefore be at least initially to activate Pelli-
nos, such that they can cause K63-linked polyubiquitination of
IRAK1. Most interestingly, this recruits NEMO to IRAK1, with
NEMO binding to polyubiquitin. There is also evidence that
TRAF6 ubiquitinates IRAK1 (Conze et al., 2008). It therefore ap-
pears that the mechanism to activate the IKK complex involves
recruiting the complex to IRAK1. This may be the mechanism
to bring TAK1 into close proximity with the IKKs to allow for their
activation. These studies therefore for the first time allow us to ki-
netically map the covalent modifications that lead to assembly of
the complex that triggers NF-kB activation, with both phosphor-
ylation and ubiquitination playing key roles (Figure 3). Ultimately,
both IRAK1 and the Pellinos (which also undergo ubiquitination)
are probably degraded to terminate the signal.The importance of ubiquitination for TLR signaling in vivo has
been emphasized in two studies. A20 is a key ubiquitin-editing
enzyme that restricts TLR responses by regulating the ubiquiti-
nation of key signaling proteins such as Traf6. A20-deficient
mice have a severe phenotype, with multiorgan inflammation
and premature death. Crossing thesemicewithMyD88-deficient
mice rescues this phenotype (Turer et al., 2008). This is because
the phenotype is due to TLR activation by commensal bacteria.
A20 is therefore key to keeping overactivation of TLRs in check,
by targeting K63-linked polyubiquination of proteins such as
Traf6. In the second study, a protein termed TRIM30-alpha,
which has a RING finger (often indicative of E3 ubiquitin ligase
activity) was shown to limit TLR signaling by targeting TAB2
and TAB3, causing their degradation. This effect was not via
the ubiquitin-proteasome pathway, however, but depended on
lysosomal degradation (Shi et al., 2008). This study points to
the importance of TAB2 and TAB3 (and, by association, TAK1)
in TLR signaling and emphasizes gaps in our knowledge of the
regulation of TLR signaling by ubiquitination.
Crosstalk with Glucocorticoids
Finally, work on the effects of glucocorticoids on TLR signaling
have revealed complex crosstalk mechanisms to explain their
anti-inflammatory effects. Multiple targets for glucocorticoids
have been reported over the years, notably effects on the NF-kB
pathway (Clark, 2007). Recently, it has been shown that glu-
cocorticoids can inhibit activation of p38 MAP kinase by TLRs.
The mechanism was shown to involve induction of a phospha-
tase termed MKP-1 (Lasa et al., 2002; Abraham et al., 2006;
Zhao et al., 2006), which dephosphorylates p38 and thereby
inactivates it. It was shown that MKP-1-deficient mice are less
susceptible to the inhibitory effects of glucocorticoids, pointingImmunity 29, July 18, 2008 ª2008 Elsevier Inc. 17
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Reviewto the importance of this process for the effects of glucocorti-
coids in vivo (Abraham et al., 2006). Another study demonstrated
that glucocorticoids appear especially potent at inhibiting the
induction of IRF3-dependent genes by TLR4 but not TLR3
(Ogawa et al., 2005). This apparent specificity was shown to
be due to the targeting of a p65-IRF3 complex, which had
been shown to be activated by TLR4 but not TLR3 (Wietek
et al., 2003). However, two other studies indicate that the effect
of glucocorticoidsmay not be restricted to TLR4 relative to TLR3.
GRIP1 is a protein that interacts with the glucocorticoid receptor.
A yeast two-hybrid screen isolated IRF3 as an interacting
protein, and it was shown that GRIP1 was required for IRF3-me-
diated transactivation. Importantly the glucocorticoid receptor
competed with IRF3 for GRIP1 and thereby blocked IRF3-medi-
ated gene expression (Reily et al., 2006). This was the case for
both TLR3 and TLR4. In addition, another study has shown
that activation of TBK-1, the upstream kinase for IRF3, is in-
hibited by glucocorticoids (McCoy et al., 2008), again pointing
to a more general mechanism rather than inhibition of TLR4 spe-
cifically. It may be that for lower doses of glucocorticoids, there is
a tendency toward TLR4 specificity, but this would have to be
tested systematically.
Conclusions
Signaling pathways activated by TLRs continue to reveal novelty
and complexity. Additional components and regulation of known
components continue to be uncovered. Importantly, several
other signaling systems have an impact on TLR signaling, nota-
bly signals activated by other innate receptors, tyrosine kinases
and tyrosine phosphatases, ubiquitinating systems, and gluco-
corticoids. These interactions will obviously be context depen-
dent and may be cell-type specific. However, the characteriza-
tion of these interactions is an important goal, because it will
provide us with models to explain TLR signaling in vivo, during
infection and inflammation.
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